作者
Maria-Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, Maria Veatriki Christodoulou, John S Tzartos, Dimitrios Tzanetakos, Dimitrios Kitsos, Maria Chondrogianni, Vasiliki Zouvelou, Efthimios Dardiotis, Elias Tzavellas, Ekaterini Syrigou, Vassiliki Benetou, George P Paraskevas, Sotirios Tsiodras, Georgios Tsivgoulis, Sotirios Giannopoulos
发表日期
2023/4
来源
Multiple Sclerosis Journal
卷号
29
期号
4-5
页码范围
585-594
出版商
SAGE Publications
简介
Background
Data are sparse regarding the safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (MS).
Objective
To estimate (1) the pooled proportion of MS patients experiencing relapse among vaccine recipients; (2) the rate of transient neurological worsening, adverse events, and serious adverse events; (3) the previous outcomes of interest for different SARS-CoV-2 vaccine types.
Methods
Systematic review and meta-analysis of pharmacovigilance registries and observational studies.
Results
Nineteen observational studies comprising 14,755 MS patients who received 23,088 doses of COVID-19 vaccines were included. Mean age was 43.3 years (95% confidence interval (CI): 40–46.6); relapsing-remitting, secondary-progressive, primary-progressive MS and clinically isolated syndrome were diagnosed in 82.6% (95% CI: 73.9–89.8), 12.6% (95% CI …
学术搜索中的文章
MI Stefanou, L Palaiodimou, A Theodorou… - Multiple Sclerosis Journal, 2023